MADEJUST BIOTECH CORP.

Being Just is the solution.
Being Just is medicine.

The MadeJust platform

We are on a mission to develop business solutions in a just manner. By generating significant, measurable value for all our stakeholders—patients, employees, investors, & the planet—our goal is to be the blueprint for all responsible enterprises.

Key pharma industry challenges we’re addressing.

Exploitative pricing

Life-saving medications are among the most expensive medicines on the market.

Environmental harm

Certain pharma companies emit more greenhouse gases than the world’s leading automotive manufacturers.

Supply chain insecurity

A deficient global supply chain means North Americans are continually forced to rely on external—often undesirable—sources for essential medicines.

Unjust access

Essential medicine costs vary significantly from country to country, indicating unjust access for patients in need.

Why MadeJust?

Because being just is the solution.

MadeJust operates as a fundamentally just platform. By bridging a just manufacturing process & pharmaceutical supply chain, we are setting the new standard for demonstrably maximizing stakeholder & shareholder value.

Bringing stakeholders real value
A just platform is beneficial to everyone involved. So how are we establishing a just platform? By ensuring a just supply chain, just manufacturing processes, & maintaining an unwavering commitment to customer-centricity.
Efficient manufacturing
We are revolutionizing pharmaceutical manufacturing via Industry 4.0 technologies, which means increased interconnectivity & sophisticated automation.
Essential industry experience
MadeJust’s team holds the necessary expertise to favourably navigate today’s drug development landscape & complex Health Canada regulations.
Social & environmental accountability
We intend to be the first pharmaceutical manufacturing company to receive a B Corp certification through emission-free operations.

Our ‘Made in Canada’ advantage.

Our ‘Made In Canada’ advantage ensures we deliver the highest-quality products while strengthening Canada’s ability to supply its citizens—& the world—with indispensable medicines.

Internationally respected
Our ‘Made in Canada’ brand exudes reliability, which enables consumer trust & extensive global market access through international agreements.
Relatively low-cost to operate
Canada offers relatively low-cost manufacturing space, power sources (partially solar-powered), housing, convenient transportation, & access to a readily-available, qualified workforce.
Close familiarity with Canadian regulations
Our team was built to guide MadeJust towards successfully securing Canada’s pharmaceutical supply chain.
Government subsidization
Canadian government grants are openly accessible for novel pharmaceutical research & Industry 4.0 manufacturing technologies.

Why we’re starting with insulin.

Insulin is a life-saving medicine unjustly priced in the global market. MadeJust exists to develop just solutions for insulin manufacturing & distribution. We have secured an insulin active pharmaceutical ingredient (API) supply agreement & partnership for intellectual property (IP) on novel insulin drug product formulations.

Inconsistent global pricing
Insulin has a wide range of prices globally, which implies highly exploitative pricing.
Current market structure is fundamentally flawed
The global insulin market is dominated by three corporations that manufacture & sell in the U.S, representing 99% of the total value, 96% of total market volume, & 88% of product registrations.
Tremendous economic opportunity
The global human insulin market stood at USD 21.26 billion in 2018 & is projected to reach USD 27.71 billion by 2026, exhibiting a CAGR of 3.4% during the forecast period.
Future expansion plans in place
MadeJust has executed a Letter of Intent (LOI) to acquire a research & development (R&D) firm, a quality assurance analytics firm, & we have secured a manufacturing space located in Canada’s B.C. Interior, which is expandable to >100,000 sq ft.

Executive & Leadership Team

Rob O’Brien, PhD

CEO, Director and Founder

Ziad Sultanali

Founder

In Progress

Pharma CEO / Founder

Clive Burge, M. Sc.

Regulatory Expert

Do you want to be part of the just solution?

Join the just movement today.

REQUEST INVESTOR DECK

Being Just is the solution. Being Just is medicine.